Summary

The Cell & Gene Therapy Bioanalytical Testing Services Market is witnessing consistent expansion as next-generation therapies reshape the global healthcare ecosystem. These advanced treatments require precise analytical validation to ensure safety, efficacy, and compliance across clinical and commercial stages. Bioanalytical testing services are essential for assessing drug behavior, immune responses, and biomarker interactions in complex biological systems. According to Persistence Market Research, the market is projected to reach USD 603.2 Bn in 2026 and grow to USD 957.9 Bn by 2033, registering a CAGR of 6.80% over the forecast period.

Market Insights

The increasing complexity of cell and gene therapies is driving demand for specialized bioanalytical testing capabilities. With the growing number of clinical trials in gene editing, cell-based immunotherapies, and regenerative medicine, testing services have become critical for validating therapeutic outcomes and meeting regulatory standards.

Advancements in analytical technologies, including high-sensitivity assays and next-generation sequencing, are significantly improving testing accuracy and efficiency. Service providers are increasingly adopting innovative platforms to handle complex biologics and large datasets, supporting faster and more reliable results.

The shift toward personalized medicine is further reinforcing the need for tailored testing solutions. Bioanalytical service providers are expanding their capabilities to address the unique requirements of individualized therapies, strengthening their role in the drug development value chain.

Drivers

A major factor supporting market growth is the rapid increase in approvals and pipelines for cell and gene therapies. Pharmaceutical and biotechnology companies are focusing on innovative treatments for oncology, rare diseases, and chronic conditions, all of which require advanced analytical validation.

Outsourcing trends are also accelerating market expansion. Organizations are relying on specialized service providers to access advanced technologies, reduce infrastructure costs, and enhance operational efficiency. Contract research organizations offer scalable solutions that align with evolving regulatory requirements.

Additionally, the growing emphasis on precision medicine is increasing the demand for highly accurate and reproducible testing methodologies. As therapies become more targeted, the need for detailed analytical insights continues to rise.

Business Opportunity

The market offers strong growth opportunities for companies providing integrated bioanalytical solutions. Providers capable of delivering comprehensive services across pharmacokinetics, pharmacodynamics, and biomarker analysis are likely to gain a competitive edge.

Emerging economies present significant expansion potential due to increasing investments in biotechnology and clinical research. Asia Pacific, in particular, is becoming a preferred destination for outsourced testing services, supported by cost advantages and improving research infrastructure.

Technological integration, including automation and advanced data analytics, is creating new avenues for innovation. Companies leveraging these capabilities can enhance service quality, improve turnaround times, and strengthen client relationships.

Region Analysis

North America holds a leading position in the market, driven by a strong biotechnology sector, advanced research capabilities, and supportive regulatory frameworks. The region continues to attract substantial investments in cell and gene therapy development.

Europe remains a key contributor, with growing research initiatives and favorable government policies supporting advanced therapeutics. Countries such as Germany, the United Kingdom, and France are at the forefront of innovation.

Asia Pacific is emerging as a high-growth region due to increasing clinical trial activity, expanding pharmaceutical manufacturing, and rising outsourcing demand. Nations including China and India are playing a pivotal role in regional growth.

Latin America and the Middle East & Africa are gradually advancing, supported by improving healthcare systems and increasing awareness of advanced treatment options.

Key Players

• BioAgilytix Labs

• KCAS Bioanalytical Services

• CD BioSciences

• Laboratory Corporation of America Holdings

• Pharmaceutical Product Development, Inc.

• Prolytix

• Pharmaron

• Charles River Laboratories

• Syneos Health

• SGS S.A.

Segmentation

By Test Type

• Bioavailability Bioavailability & Bioequivalence Studies

• Pharmacokinetics

• Pharmacodynamics

• Non-clinical

• Tissue Bioanalysis

• Miscellaneous

By Therapy Type

• Gene Therapy

• Gene-Modified Cell Therapy

• Cell Therapy

By End User

• Non-Clinical Contract Manufacturing Organizations (CMO)

• Pharma and Biopharma Companies

• Contract Research Organizations (CRO)

By Indication

• Oncology Cancer

• Infectious Diseases

• Neurological Disorders

• Cardiovascular Disorders

• Gastrointestinal Diseases

• Autoimmune Diseases

• Others

By Geographic Coverage

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Cell & Gene Therapy Bioanalytical Testing Services Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2026
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. COVID-19 Impact Analysis
2.5. Porter's Five Forces Analysis
2.6. Impact of Russia-Ukraine Conflict
2.7. PESTLE Analysis
2.8. Regulatory Analysis
2.9. Price Trend Analysis
2.9.1. Current Prices and Future Projections, 2025-2033
2.9.2. Price Impact Factors
3. Global Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, 2020-2033
3.1. Global Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, Value (US$ Mn), 2020-2033
3.1.1. Bioavailability Bioavailability & Bioequivalence Studies
3.1.2. Pharmacokinetics
3.1.3. Pharmacodynamics
3.1.4. Non-clinical
3.1.5. Tissue Bioanalysis
3.1.6. Miscellaneous
3.2. Global Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, Value (US$ Mn), 2020-2033
3.2.1. Gene Therapy
3.2.2. Gene-Modified Cell Therapy
3.2.3. Gene-Modified Cell Therapy
3.2.3.1. Cell Therapy
3.3. Global Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, Value (US$ Mn), 2020-2033
3.3.1. Non-Clinical Contract Manufacturing Organizations (CMO)
3.3.2. Pharma and Biopharma Companies
3.3.3. Contract Research Organizations (CRO)
3.4. Global Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, Value (US$ Mn), 2020-2033
3.4.1. Oncology Cancer
3.4.2. Infectious Diseases
3.4.3. Neurological disorders
3.4.4. Cardiovascular Disorders
3.4.5. Gastrointestinal Diseases
3.4.6. Autoimmune Diseases
3.4.7. Others
3.5. Global Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Region, Value (US$ Mn), 2020-2033
3.5.1. North America
3.5.2. Europe
3.5.3. Asia Pacific
3.5.4. Latin America
3.5.5. Middle East & Africa
4. North America Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, 2020-2033
4.1. North America Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, Value (US$ Mn), 2020-2033
4.1.1. Bioavailability Bioavailability & Bioequivalence Studies
4.1.2. Pharmacokinetics
4.1.3. Pharmacodynamics
4.1.4. Non-clinical
4.1.5. Tissue Bioanalysis
4.1.6. Miscellaneous
4.2. North America Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, Value (US$ Mn), 2020-2033
4.2.1. Gene Therapy
4.2.2. Gene-Modified Cell Therapy
4.2.3. Gene-Modified Cell Therapy
4.2.3.1. Cell Therapy
4.3. North America Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, Value (US$ Mn), 2020-2033
4.3.1. Non-Clinical Contract Manufacturing Organizations (CMO)
4.3.2. Pharma and Biopharma Companies
4.3.3. Contract Research Organizations (CRO)
4.4. North America Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, Value (US$ Mn), 2020-2033
4.4.1. Oncology Cancer
4.4.2. Infectious Diseases
4.4.3. Neurological disorders
4.4.4. Cardiovascular Disorders
4.4.5. Gastrointestinal Diseases
4.4.6. Autoimmune Diseases
4.4.7. Others
4.5. North America Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Country, Value (US$ Mn), 2020-2033
4.5.1. U.S. Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
4.5.2. U.S. Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
4.5.3. U.S. Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
4.5.4. U.S. Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
4.5.5. Canada Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
4.5.6. Canada Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
4.5.7. Canada Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
4.5.8. Canada Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
4.6. BPS Analysis/Market Attractiveness Analysis
5. Europe Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, 2020-2033
5.1. Europe Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, Value (US$ Mn), 2020-2033
5.1.1. Bioavailability Bioavailability & Bioequivalence Studies
5.1.2. Pharmacokinetics
5.1.3. Pharmacodynamics
5.1.4. Non-clinical
5.1.5. Tissue Bioanalysis
5.1.6. Miscellaneous
5.2. Europe Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, Value (US$ Mn), 2020-2033
5.2.1. Gene Therapy
5.2.2. Gene-Modified Cell Therapy
5.2.3. Gene-Modified Cell Therapy
5.2.3.1. Cell Therapy
5.3. Europe Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, Value (US$ Mn), 2020-2033
5.3.1. Non-Clinical Contract Manufacturing Organizations (CMO)
5.3.2. Pharma and Biopharma Companies
5.3.3. Contract Research Organizations (CRO)
5.4. Europe Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, Value (US$ Mn), 2020-2033
5.4.1. Oncology Cancer
5.4.2. Infectious Diseases
5.4.3. Neurological disorders
5.4.4. Cardiovascular Disorders
5.4.5. Gastrointestinal Diseases
5.4.6. Autoimmune Diseases
5.4.7. Others
5.5. Europe Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Country, Value (US$ Mn), 2020-2033
5.5.1. Germany Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
5.5.2. Germany Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
5.5.3. Germany Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
5.5.4. Germany Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
5.5.5. Italy Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
5.5.6. Italy Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
5.5.7. Italy Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
5.5.8. Italy Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
5.5.9. France Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
5.5.10. France Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
5.5.11. France Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
5.5.12. France Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
5.5.13. U.K. Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
5.5.14. U.K. Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
5.5.15. U.K. Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
5.5.16. U.K. Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
5.5.17. Spain Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
5.5.18. Spain Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
5.5.19. Spain Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
5.5.20. Spain Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
5.5.21. Russia Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
5.5.22. Russia Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
5.5.23. Russia Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
5.5.24. Russia Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
5.5.25. Rest of Europe Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
5.5.26. Rest of Europe Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
5.5.27. Rest of Europe Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
5.5.28. Rest of Europe Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
5.6. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, 2020-2033
6.1. Asia Pacific Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, Value (US$ Mn), 2020-2033
6.1.1. Bioavailability Bioavailability & Bioequivalence Studies
6.1.2. Pharmacokinetics
6.1.3. Pharmacodynamics
6.1.4. Non-clinical
6.1.5. Tissue Bioanalysis
6.1.6. Miscellaneous
6.2. Asia Pacific Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, Value (US$ Mn), 2020-2033
6.2.1. Gene Therapy
6.2.2. Gene-Modified Cell Therapy
6.2.3. Gene-Modified Cell Therapy
6.2.3.1. Cell Therapy
6.3. Asia Pacific Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, Value (US$ Mn), 2020-2033
6.3.1. Non-Clinical Contract Manufacturing Organizations (CMO)
6.3.2. Pharma and Biopharma Companies
6.3.3. Contract Research Organizations (CRO)
6.4. Asia Pacific Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, Value (US$ Mn), 2020-2033
6.4.1. Oncology Cancer
6.4.2. Infectious Diseases
6.4.3. Neurological disorders
6.4.4. Cardiovascular Disorders
6.4.5. Gastrointestinal Diseases
6.4.6. Autoimmune Diseases
6.4.7. Others
6.5. Asia Pacific Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Country, Value (US$ Mn), 2020-2033
6.5.1. China Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
6.5.2. China Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
6.5.3. China Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
6.5.4. China Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
6.5.5. Japan Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
6.5.6. Japan Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
6.5.7. Japan Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
6.5.8. Japan Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
6.5.9. South Korea Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
6.5.10. South Korea Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
6.5.11. South Korea Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
6.5.12. South Korea Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
6.5.13. India Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
6.5.14. India Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
6.5.15. India Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
6.5.16. India Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
6.5.17. Southeast Asia Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
6.5.18. Southeast Asia Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
6.5.19. Southeast Asia Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
6.5.20. Southeast Asia Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
6.5.21. Rest of SAO Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
6.5.22. Rest of SAO Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
6.5.23. Rest of SAO Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
6.5.24. Rest of SAO Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
6.6. BPS Analysis/Market Attractiveness Analysis
7. Latin America Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, 2020-2033
7.1. Latin America Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, Value (US$ Mn), 2020-2033
7.1.1. Bioavailability Bioavailability & Bioequivalence Studies
7.1.2. Pharmacokinetics
7.1.3. Pharmacodynamics
7.1.4. Non-clinical
7.1.5. Tissue Bioanalysis
7.1.6. Miscellaneous
7.2. Latin America Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, Value (US$ Mn), 2020-2033
7.2.1. Gene Therapy
7.2.2. Gene-Modified Cell Therapy
7.2.3. Gene-Modified Cell Therapy
7.2.3.1. Cell Therapy
7.3. Latin America Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, Value (US$ Mn), 2020-2033
7.3.1. Non-Clinical Contract Manufacturing Organizations (CMO)
7.3.2. Pharma and Biopharma Companies
7.3.3. Contract Research Organizations (CRO)
7.4. Latin America Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, Value (US$ Mn), 2020-2033
7.4.1. Oncology Cancer
7.4.2. Infectious Diseases
7.4.3. Neurological disorders
7.4.4. Cardiovascular Disorders
7.4.5. Gastrointestinal Diseases
7.4.6. Autoimmune Diseases
7.4.7. Others
7.5. Latin America Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Country, Value (US$ Mn), 2020-2033
7.5.1. Brazil Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
7.5.2. Brazil Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
7.5.3. Brazil Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
7.5.4. Brazil Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
7.5.5. Mexico Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
7.5.6. Mexico Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
7.5.7. Mexico Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
7.5.8. Mexico Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
7.5.9. Argentina Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
7.5.10. Argentina Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
7.5.11. Argentina Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
7.5.12. Argentina Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
7.5.13. Rest of LATAM Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
7.5.14. Rest of LATAM Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
7.5.15. Rest of LATAM Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
7.5.16. Rest of LATAM Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
7.6. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, 2020-2033
8.1. Middle East & Africa Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, Value (US$ Mn), 2020-2033
8.1.1. Bioavailability Bioavailability & Bioequivalence Studies
8.1.2. Pharmacokinetics
8.1.3. Pharmacodynamics
8.1.4. Non-clinical
8.1.5. Tissue Bioanalysis
8.1.6. Miscellaneous
8.2. Middle East & Africa Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, Value (US$ Mn), 2020-2033
8.2.1. Gene Therapy
8.2.2. Gene-Modified Cell Therapy
8.2.3. Gene-Modified Cell Therapy
8.2.3.1. Cell Therapy
8.3. Middle East & Africa Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, Value (US$ Mn), 2020-2033
8.3.1. Non-Clinical Contract Manufacturing Organizations (CMO)
8.3.2. Pharma and Biopharma Companies
8.3.3. Contract Research Organizations (CRO)
8.4. Middle East & Africa Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, Value (US$ Mn), 2020-2033
8.4.1. Oncology Cancer
8.4.2. Infectious Diseases
8.4.3. Neurological disorders
8.4.4. Cardiovascular Disorders
8.4.5. Gastrointestinal Diseases
8.4.6. Autoimmune Diseases
8.4.7. Others
8.5. Middle East & Africa Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Country, Value (US$ Mn), 2020-2033
8.5.1. GCC Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
8.5.2. GCC Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
8.5.3. GCC Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
8.5.4. GCC Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
8.5.5. South Africa Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
8.5.6. South Africa Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
8.5.7. South Africa Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
8.5.8. South Africa Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
8.5.9. Egypt Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
8.5.10. Egypt Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
8.5.11. Egypt Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
8.5.12. Egypt Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
8.5.13. Nigeria Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
8.5.14. Nigeria Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
8.5.15. Nigeria Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
8.5.16. Nigeria Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
8.5.17. Rest of Middle East Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Test Type, 2020-2033
8.5.18. Rest of Middle East Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Therapy Type, 2020-2033
8.5.19. Rest of Middle East Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by End user, 2020-2033
8.5.20. Rest of Middle East Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, by Indication, 2020-2033
8.6. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Vs Segment Heatmap
9.2. Company Market Share Analysis, 2025
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. BioAgilytix Labs
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Developments
9.4.2. KCAS Bioanalytical Services
9.4.3. CD BioSciences
9.4.4. Laboratory Corporation of America Holdings
9.4.5. Pharmaceutical Product Development, Inc.
9.4.6. Prolytix
9.4.7. Pharmaron
9.4.8. Charles River Laboratories
9.4.9. Syneos Health
9.4.10. SGS S.A.
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations